Express Pharma

APRIL 17, 2024

Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 GlobalData’s Pharma Intelligence Center Deals Database reveals that MASH drugs secured over $5.7

Drug Development 76

Drug Development Diabetes 76

Pharmaceutical Technology

MAY 19, 2023

It received approval from the US Food and Drug Administration in October 2018. Yutiq is indicated to treat chronic, non-infectious uveitis that affects the posterior segment of the eye.

Diabetes 52

Diabetes Drug Development 52

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The nomination of a first candidate in the collaboration that will advance into development triggers a $2.5

Diabetes 60

Diabetes Drug Development 60

European Pharmaceutical Review

SEPTEMBER 21, 2023

In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. 4,5 What is the key consideration drug developers should apply to gene therapies?

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Express Pharma

NOVEMBER 1, 2024

In the marathon of drug development, where billions of dollars and over a decade of research are the norm, drug repurposing is quietly reshaping the landscape. Challenges in drug repurposing Despite these technological and regulatory advancements, the journey of drug repurposing is not without its challenges.

Drug Development 100

Drug Development Compounding Generic Medicine Vaccines 100

Quality Matters

APRIL 4, 2023

Novel biologics and biosimilars – or biologics highly similar to an existing biologic already approved – also hold great promise to help increase availability of quality biologic medicines for conditions ranging from diabetes to cancer. Another example is mRNA vaccines.

Biosimilars 52

Biosimilars Vaccines Drug Development Diabetes 52